NEW STAFF APPOINTMENT: KAREN SIU, PhD- Programme Manager- Medical Device Development
Dr Karen Siu obtained her PhD from Monash University in 2003 in X-ray Physics. Her postdoctoral work as an Australian Synchrotron Research Program Fellow allowed her to explore the applications of synchrotrons, or highly intense x-ray sources, to biomedical research studying cancers of the brain and breast. She focussed on synchrotron imaging for understanding the […]
4Dx To Close Series A Capital Raise
Melbourne, Australia, November 23, 2016: 4Dx Limited is pleased to announce that, due to an overwhelming response, as of 5pm, Friday, 9th December, 2016, the company’s $4m Series A capital round will be officially closed. It is anticipated that the round will close oversubscribed. 4Dx founder and Chairman, Andreas Fouras, said, “4Dx is extremely pleased […]
A BREATH OF FRESH AIR FOR MEDICAL IMAGE TECHNOLOGY
4Dx was featured in an article in Australias national daily newspaper, The Australian today. Andreas Fouras, Founder and CEO of 4Dx is interviewed and the article discusses the new software for imaging lung function devised by 4Dx. A BREATH OF FRESH AIR FOR MEDICAL IMAGE TECHNOLOGY A “dream job” studying airflow through jet engines has […]
Appointment of General Manager – Notting Hill Devices
4Dx is excited to announce that Paul Cooke will be taking on the role of General Manager of 4Dx’s specialist hardware subsidiary, Notting Hill Devices. As Paul moves into this role, he will be stepping aside from his role as Non-Executive Director, effective 1st September. During his tenure as Non-Executive Director, Paul played a key […]
Monash license agreement changes
A number of positive changes have been made to the key licence agreement with Monash University (which grants 4Dx rights to commercialise this technology in exchange for royalty payments). Most notable among these changes is that the funding threshold for assignment of patents has been lowered to A$6.5 million from A$10 million. Once this lower […]
Andreas Fouras, CEO of 4Dx, says backing bright people is a bright idea
Andreas Fouras, Founder and CEO of 4Dx, spoke with Nature Index on the recent call from the National Health and Medical Research Council (NHMRC) for public consultation on the structural review of their grant program. Following criticism that current funding models are failing to support researchers across all stages of their careers, the NHMRC have opened the debate around three proposed alternative models to […]
4Dx retail round closes with full subscription
We are pleased to announce that our recent retail offer of shares is now fully subscribed after successfully raising AU$500,000. It is very encouraging to gain backing so enthusiastically from retail investors committed to seeing our technology come to market as fast as possible. These funds take us a step closer to commercialising our technology through ongoing clinical […]
AuntMinnie.com interview 4Dx on their advanced visualization tool being used for imaging lung disease
4Dx was interviewed by AuntMinnie.com, an influential community site for radiologists and related professionals in the medical imaging industry. In the article “Advanced visualization tool assesses lung disease”, Eric Barnes interviewed the 4Dx team on the new technique they have developed that combines fluoroscopy and advanced visualization to generate high-resolution images of the motion and […]
4Dx’s CEO talks to the Australian Financial Review about how our culture is stifling innovation
The AFR cover insights from last weeks meeting of 400 of the top people in the innovation sector, where Andreas Fouras, CEO of 4Dx, highlighted one of the biggest problems Australia faces as it seeks to become high tech nation. Contrary to the risk taking the government would lead us to believe is encouraged as a nation, when […]
Yahoo! Finance announces 4Dx as one of five promising new technologies in the fight against lung disease
Yahoo! Finance (via CEOCFO Magazine) has announced 4Dx as one of five innovative new approaches for diagnosis and treatment of lung disease that has the potential to reduce the human and financial toll. Click here to read the full article.
